BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Lyu Z, Yang M, Yang T, Ma M, Yang Z. Metal-Regulatory Transcription Factor-1 Targeted by miR-148a-3p Is Implicated in Human Hepatocellular Carcinoma Progression. Front Oncol 2021;11:700649. [PMID: 34660270 DOI: 10.3389/fonc.2021.700649] [Reference Citation Analysis]
2 Biglow L, Ashraf S, Alsharedi M. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investig 2021;8:22. [PMID: 34917675 DOI: 10.21037/sci-2021-029] [Reference Citation Analysis]
3 Sun X, Li L, Xu L, Zhou Z, Chen J, Wang J, Zhang Y, Hu D, Chen M. Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria. BMC Cancer 2021;21:147. [PMID: 33563246 DOI: 10.1186/s12885-021-07870-0] [Reference Citation Analysis]
4 Aitcheson G, Pillai A, Dahman B, John BV. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Curr Hepatol Rep 2021;:1-11. [PMID: 33552839 DOI: 10.1007/s11901-021-00560-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med 2021;62:1235-41. [PMID: 33509970 DOI: 10.2967/jnumed.120.257915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee HA, Chu KB, Moon EK, Quan FS. Glutathione Peroxidase 8 Suppression by Histone Deacetylase Inhibitors Enhances Endoplasmic Reticulum Stress and Cell Death by Oxidative Stress in Hepatocellular Carcinoma Cells. Antioxidants (Basel) 2021;10:1503. [PMID: 34679638 DOI: 10.3390/antiox10101503] [Reference Citation Analysis]
7 Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY, Lv JJ, Zhang Z, Chen ZN, Bian H. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front Cell Dev Biol 2019;7:233. [PMID: 31681766 DOI: 10.3389/fcell.2019.00233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
8 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
9 Mauda-Havakuk M, Mikhail AS, Starost MF, Jones EC, Karim B, Kleiner DE, Partanen A, Esparza-Trujillo JA, Bakhutashvili I, Wakim PG, Kassin MT, Lewis AL, Karanian JW, Wood BJ, Pritchard WF. Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. J Hepatocell Carcinoma 2021;8:71-83. [PMID: 33728278 DOI: 10.2147/JHC.S287800] [Reference Citation Analysis]
10 Yin L, Xia Y, Xu P, Zheng W, Gao Y, Xie F, Ji Z. Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death. Oncol Rep 2020;44:477-86. [PMID: 32468056 DOI: 10.3892/or.2020.7622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang Z, Qu K, Zhou L, Ren L, Ren B, Meng F, Yu W, Wang H, Fan H. Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;577:45-51. [PMID: 34507064 DOI: 10.1016/j.bbrc.2021.08.030] [Reference Citation Analysis]
12 Li D, Crook C, Ballena R, Fakih M. Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution? JCO Oncol Pract 2021;17:164-6. [PMID: 33596100 DOI: 10.1200/OP.20.01018] [Reference Citation Analysis]
13 Lin J, Ruan J, Zhu H, Chen Z, Chen J, Yu H. Tenacissoside H Induces Autophagy and Radiosensitivity of Hepatocellular Carcinoma Cells by PI3K/Akt/mTOR Signaling Pathway. Dose Response 2021;19:15593258211011023. [PMID: 34035782 DOI: 10.1177/15593258211011023] [Reference Citation Analysis]
14 Sun X, Yang Z, Tang Y, Mao S, Xiong P, Wang J, Chen J, Zhang Y, Chen M, Xu L. Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy 2021. [PMID: 34758630 DOI: 10.2217/imt-2021-0057] [Reference Citation Analysis]
15 Reinkens T, Stalke A, Huge N, Vajen B, Eilers M, Schäffer V, Dittrich-Breiholz O, Schlegelberger B, Illig T, Skawran B. Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma. J Cancer 2022;13:62-75. [PMID: 34976171 DOI: 10.7150/jca.66016] [Reference Citation Analysis]
16 Lee YS, Jeong S, Kim KY, Yoon JS, Kim S, Yoon KS, Ha J, Kang I, Choe W. Honokiol inhibits hepatoma carcinoma cell migration through downregulated Cyclophilin B expression. Biochem Biophys Res Commun 2021;552:44-51. [PMID: 33743348 DOI: 10.1016/j.bbrc.2021.03.011] [Reference Citation Analysis]
17 Zhang BH, Cai YS, Jiang L, Yang JY. Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:737-40. [PMID: 34760990 DOI: 10.21037/hbsn-21-304] [Reference Citation Analysis]
18 Borde T, Nezami N, Gaupp FL, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022;:212426. [PMID: 35412368 DOI: 10.1148/radiol.212426] [Reference Citation Analysis]
19 Chen M, Hu J, Cao J, Cai X. Comprehensive Consideration before the Decision-Making of the Systemic Treatment in Patients with Advanced Hepatocellular Carcinoma. Liver cancer. 2019;. [PMID: 32399435 DOI: 10.1159/000502775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, Kanayama K, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Muroyama R, Kato J, Mimura N, Kanda T, Maruyama H, Kato N. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;549:171-8. [PMID: 33676186 DOI: 10.1016/j.bbrc.2021.02.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer 2021;127:865-74. [PMID: 33231873 DOI: 10.1002/cncr.33317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, Yu Z, Liu L, Liu X, Li B, Zheng J. Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:8125-40. [PMID: 32884295 DOI: 10.2147/OTT.S263047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol 2020;13:623-9. [PMID: 32394749 DOI: 10.1080/17512433.2020.1767591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wu Z, Wei C, Wang L, He L. Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:9991533. [PMID: 34306165 DOI: 10.1155/2021/9991533] [Reference Citation Analysis]
25 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
26 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yin W, Xu J, Li C, Dai X, Wu T, Wen J. Plantamajoside inhibits the proliferation and epithelial-to-mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia-inducible factor-1α-dependent gene expression. Cell Biol Int 2020;44:1616-27. [PMID: 32239594 DOI: 10.1002/cbin.11354] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Yu JH, Ma S. Organoids as research models for hepatocellular carcinoma. Exp Cell Res 2021;411:112987. [PMID: 34942189 DOI: 10.1016/j.yexcr.2021.112987] [Reference Citation Analysis]
29 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
30 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
31 Sun X, Mei J, Lin W, Yang Z, Peng W, Chen J, Zhang Y, Xu L, Chen M. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer 2021;21:775. [PMID: 34218801 DOI: 10.1186/s12885-021-08428-w] [Reference Citation Analysis]
32 Komoll RM, Hu Q, Olarewaju O, von Döhlen L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, Sharma AD, Goga A, Ott M, Balakrishnan A. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol 2021;74:122-34. [PMID: 32738449 DOI: 10.1016/j.jhep.2020.07.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
33 Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:991-1001. [PMID: 34051880 DOI: 10.1016/S1470-2045(21)00151-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
34 Hong TH, Jeena MT, Kim OH, Kim KH, Choi HJ, Lee KH, Hong HE, Ryu JH, Kim SJ. Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells. Sci Rep 2021;11:874. [PMID: 33441650 DOI: 10.1038/s41598-020-79536-z] [Reference Citation Analysis]
35 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433 [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Reference Citation Analysis]
36 Barry AE, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez DA, Kirton KJ, Shah AP, Dang H. Hepatic Stellate Cells and Hepatocarcinogenesis. Front Cell Dev Biol 2020;8:709. [PMID: 32850829 DOI: 10.3389/fcell.2020.00709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
37 Nervo A, Ragni A, Piovesan A, Marica V, Migliore E, Gallo M, Arvat E. Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation. Eur Thyroid J 2021;10:65-71. [PMID: 33777821 DOI: 10.1159/000508186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]